Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

54.87USD
23 Feb 2018
Change (% chg)

$0.30 (+0.55%)
Prev Close
$54.57
Open
$54.82
Day's High
$55.00
Day's Low
$54.57
Volume
2,934,245
Avg. Vol
3,997,885
52-wk High
$66.80
52-wk Low
$53.36

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $176,050.70
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.91

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

Merck to buy virus-based cancer drug firm Viralytics for $394 million

U.S. drugmaker Merck & Co , already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its pipeline in the sector.

21 Feb 2018

Merck to buy virus-based cancer drug firm Viralytics for $394 million

U.S. drugmaker Merck & Co , already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars (282.58 million pounds)to expand its pipeline in the sector.

21 Feb 2018

UPDATE 2-Merck to buy virus-based cancer drug firm Viralytics for $394 mln

* "Tuck-in" deal broadens Merck's immuno-oncology line-up (Adds analyst comment, more on virus science)

21 Feb 2018

Merck to buy Viralytics for $394 mln to boost immuno-oncology

Feb 21 U.S. drugmaker Merck & Co, already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its drug pipeline.

21 Feb 2018

BRIEF-Merck And Viralytics Announce Acquisition Agreement

* MERCK AND VIRALYTICS ANNOUNCE ACQUISITION AGREEMENT, EXPANDING MERCK'S LEADING IMMUNO-ONCOLOGY PIPELINE

21 Feb 2018

Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

17 Feb 2018

UPDATE 1-Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

17 Feb 2018

Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

17 Feb 2018

BRIEF-Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1

* SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR NEUROFIBROMATOSIS TYPE 1

15 Feb 2018

BRIEF-Nestle declines to comment on interest in Pfizer, Merck units

* CEO SAYS NO COMMENT ON INTEREST IN PFIZER, MERCK CONSUMER HEALTH UNITS, BUT IS GENERALLY INTERESTED IN EXPANDING ITS CONSUMER HEALTH BUSINESS

15 Feb 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $132.02 +2.11
Pfizer Inc. (PFE.N) $36.26 +0.52
AbbVie Inc (ABBV.N) $118.75 +1.19
Eli Lilly and Co (LLY.N) $78.75 +1.56
Bristol-Myers Squibb Co (BMY.N) $67.95 +2.01
Bristol-Myers Squibb Co (BMYMP.PK) $1,306.55 +216.55

Earnings vs. Estimates